| Revenue growth | Net sales +14% YoY; -5.3% QoQ; H1 +23.1% YoY. |
|---|---|
| Margins | EBITDA margin 25.1% vs 31.3% YoY, 30.0% QoQ. |
| Demand visibility | India Rx +14.4% H1 vs IPM ~14.3%; chronic growth 19.5%. |
Growth
Net sales +14% YoY, -5.3% QoQ; India +15%, EMEA +40%, APAC +43%, API +20%; US $317mn, +1% YoY, -13% QoQ.
Outlook
No explicit growth guidance. Plans ~15 US launches, 15+ ANDA filings, 20+ India launches in FY27; ongoing cost optimisation.
Risks
Increased competition and LOE on key US products; FDA remediation at Tarapur, Mandideep Unit-1, Pithampur Unit-II; LATAM -30% YoY.
Last quarter's promises, checked
Delivered
- EBITDA margin ~25% (24-25% range) → 25.1% (= BEAT)
- EMEA growth 10-20% → +40% (= BEAT)
- US USD 250-280mn/qtr → USD 317mn (= BEAT)
Partly delivered
- ~20 India launches FY27 → 12 in H1 (= PARTIAL)
Missed
- India Rx 1.2-1.3x IPM → ~1.0x (H1 14.4% vs IPM 14.3%) (= MISS)
- ROW double-digit growth → -4% (= MISS)
Investor Presentation filed with NSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,015.90
- Market cap
- ₹92,186 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.7×Sector 41.3×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Management Change
Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.
Lupin Q2 FY27 Results: Net Profit ₹1,155 Cr, Down 22.2% YoY
Lupin Ltd reported revenue from operations of ₹7,827 Cr (+11.1% YoY) and net profit of ₹1,155 Cr (-22.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,155 Cr · -22.2% YoY
Lupin Product Launch
Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Lupin Business Update
Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.
Lupin Management Change
Lupin Limited appointed Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. He will oversee global legal, compliance, and IP functions.